Moderna, Inc. (MRNA): R&D Expense
$3.13B
Year ended 2025-12-31
$2.88B
Trailing 12 months to 2026-06-30
-1.7%
3-year compound annual growth
+18.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.13B | -31.1% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $4.54B | -6.2% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $4.84B | +47.0% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $3.29B | +65.5% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $1.99B | +45.3% | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | $1.37B | +176.2% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $496.00M | +9.2% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $454.08M | +10.6% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $410.46M | +49.4% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $274.72M | n/a | 2019-03-13, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.13B | -31.1% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $187.52M | -3.1% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $825.00M | -9.4% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $81.49M | +3.1% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.02B | +38.9% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Novavax Inc (NVAX) | 2025-12-31 | $342.32M | -12.5% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $166.13M | -4.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗